拓扑替康联合顺铂治疗晚期非小细胞肺癌的近期疗效观察

目的：分析拓扑替康联合顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法：36例晚期非小细胞肺癌患者每天给予拓扑替康2mg静滴,连续4-6d,第1天加用顺铂70mg/m2,21d为一周期,评价患者症状改善情况和1、2年生存率及药物毒副反应。结果：36例患者完全缓解1例,部分缓解13例,总有效率达38.9%。除2例尚存活外,34例已死亡,存活3-28个月,平均16-21个月,1、2年生存率分别为47.2%、13.9%。毒副反应的发生率为69.4%,其中胃肠道反应占44.4%,白细胞下降占41.7%。结论：拓扑替康联合顺铂治疗晚期非小细胞肺癌具有较好的疗效,毒副反应可以耐受。

An observation on short-term effect of the combination of topotecan and cisplatin in the treatment of advanced non-small cell lung cancer

Objective:To analyze the efficacy and toxicity of the combination of topotecan and cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods: Thirty-six patients with advanced non-small cell lung cancer were enrolled into the study, the patients received topotecan (intravenous) 2 mg daily for 4~6 days and cisplatin 70 mg/m 2 on day 1, 21-day for each cycle. At last we evaluated the improvement of symptoms, the 1 or 2-year survival rate and the adverse effects of drugs. Results: The overall response rate in the group was 38.9%, 1 patient had complete response (CR), 13 patients had partial response (PR). 2 patients were survival, 34 patients were dead, they had lived 3~28 months, the median survival time of 16~21 months. The 1 or 2-year survival rates were 47.2% and 13.9%, respectively. The occurrence rate of toxicities were 69.4%; the disorders in gastrointestinal aspects account for 44.4%, leukopenia account for 41.7%. Conclusion: The combination of topotecan and cisplatin is effective and well-tolerated in the treatment of advanced NSCLC.